ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumours.

Trial Profile

ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumours.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2012

At a glance

  • Drugs Celecoxib (Primary) ; Etoposide (Primary) ; Thalidomide (Primary)
  • Indications Brain cancer
  • Focus Therapeutic Use
  • Acronyms Angiocomb
  • Most Recent Events

    • 27 Dec 2012 Additional lead trial centers identified as reported by ClinicalTrials.gov.
    • 27 Dec 2012 Planned number of patients changed from 10 to 50 as reported by ClinicalTrials.gov.
    • 27 Dec 2012 Planned end date changed from 24 Nov 2008 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top